Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Noncoding RNA
2019 Jan 21;51:. doi: 10.3390/ncrna5010010.
Show Gene links
Show Anatomy links
MicroRNA-4719 and microRNA-6756-5p Correlate with Castration-Resistant Prostate Cancer Progression through Interleukin-24 Regulation.
Das DK
,
Persaud L
,
Sauane M
.
???displayArticle.abstract???
Prostate cancer (PCa) is the second leading cause of cancer death in the United States. The five-year survival rate for men diagnosed with localized PCa is nearly 100%, yet for those diagnosed with aggressive PCa, it is less than 30%. The pleiotropic cytokine Interleukin-24 (IL-24) has been shown to specifically kill PCa cells compared to normal cells when overexpressed in both in vitro and in vivo studies. Despite this, the mechanisms regulating IL-24 in PCa are not well understood. Since specific microRNAs (miRNAs) are dysregulated in PCa, we used miRNA target prediction algorithm tools to identify miR-4719 and miR-6556-5p as putative regulators of IL-24. This study elucidates the expression profile and role of miR-4719 and miR-6756-5p as regulators of IL-24 in PCa. qRT-PCR analysis shows miR-4719 and miR-6756-5p overexpression significantly decreases the expression of IL-24 in PCa cells compared to the negative control. Compared to the indolent PCa and normal prostate epithelial cells, miR-4719 and miR-6756-5p are significantly overexpressed in castration-resistant prostate cancer (CRPC) cell lines, indicating that their gain may be an early event in PCa progression. Moreover, miR-4719 and miR-6756-5p are significantly overexpressed in the CRPC cell line of African-American males (E006AA-hT) compared to CRPC cell lines of Caucasian males (PC-3 and DU-145), indicating that miR-4719 and miR-6756-5p may also play a role in racial disparity. Lastly, the inhibition of expression of miR-4719 and miR-6756-5p significantly increases IL-24 expression and inhibits proliferation and migration of CRPC cell lines. Our findings indicate that miR-4719 and miR-6756-5p may regulate CRPC progression through the targeting of IL-24 expression and may be biomarkers that differentiate between indolent and CRPC. Strategies to inhibit miR-4719 and miR-6756-5p expression to increase IL-24 in PCa may have therapeutic efficacy in aggressive PCa.
Figure 5. Hypothesized pathway of microRNA-4719 and microRNA-6756-5p targeting IL-24 to regulate cellular proliferation and migration in CRPC cell lines. miR-4719 and miR-6756-5p bind to IL-24 3′UTR leading to destabilization of IL-2 mRNA, a decrease in IL-24 protein production, and an increase in CRPC cell proliferation and migration.
Ayub,
Microdissecting the role of microRNAs in the pathogenesis of prostate cancer.
2015, Pubmed
Ayub,
Microdissecting the role of microRNAs in the pathogenesis of prostate cancer.
2015,
Pubmed
Bhutia,
Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24.
2010,
Pubmed
Bhutia,
Autophagy switches to apoptosis in prostate cancer cells infected with melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24).
2011,
Pubmed
Bhutia,
mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer.
2012,
Pubmed
Calin,
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.
2004,
Pubmed
Cannistraci,
MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samples.
2014,
Pubmed
Chung,
A comprehensive resequence-analysis of 250 kb region of 8q24.21 in men of African ancestry.
2014,
Pubmed
Cui,
Breast cancer identification via modeling of peripherally circulating miRNAs.
2018,
Pubmed
Dash,
Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine.
2010,
Pubmed
Dash,
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.
2011,
Pubmed
DeSantis,
Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities.
2016,
Pubmed
Do,
Sigma 1 Receptor plays a prominent role in IL-24-induced cancer-specific apoptosis.
2013,
Pubmed
Evans,
Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis.
2008,
Pubmed
Hoffman,
Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study.
2001,
Pubmed
Iorio,
MicroRNAs in cancer: small molecules with a huge impact.
2009,
Pubmed
Iorio,
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review.
2012,
Pubmed
Jones,
MicroRNAs that affect prostate cancer: emphasis on prostate cancer in African Americans.
2013,
Pubmed
Karlou,
Therapeutic targeting of the prostate cancer microenvironment.
2010,
Pubmed
Katsogiannou,
The hallmarks of castration-resistant prostate cancers.
2015,
Pubmed
Koochekpour,
Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA.
2004,
Pubmed
Koochekpour,
Establishment and characterization of a highly tumorigenic African American prostate cancer cell line, E006AA-hT.
2014,
Pubmed
Lebedeva,
Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24.
2003,
Pubmed
Lebedeva,
Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species.
2003,
Pubmed
Lu,
MicroRNA expression profiles classify human cancers.
2005,
Pubmed
Luu,
miRNAs associated with prostate cancer risk and progression.
2017,
Pubmed
Macfarlane,
MicroRNA: Biogenesis, Function and Role in Cancer.
2010,
Pubmed
Majid,
MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer.
2010,
Pubmed
Mao,
Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer.
2018,
Pubmed
Moyer,
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
2012,
Pubmed
Obinata,
Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer.
2017,
Pubmed
Otkjaer,
The p38 MAPK regulates IL-24 expression by stabilization of the 3' UTR of IL-24 mRNA.
2010,
Pubmed
Parnes,
Prostate cancer prevention: strategies for agent development.
2013,
Pubmed
Powell,
Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity.
2010,
Pubmed
Presley,
A new approach to understanding racial disparities in prostate cancer treatment.
2013,
Pubmed
Rupaimoole,
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.
2017,
Pubmed
Sauane,
Melanoma differentiation associated gene-7/interleukin-24 promotes tumor cell-specific apoptosis through both secretory and nonsecretory pathways.
2004,
Pubmed
Sauane,
Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis.
2010,
Pubmed
Sauane,
Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis.
2008,
Pubmed
Siegel,
Cancer Statistics, 2017.
2017,
Pubmed
Su,
Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2.
2006,
Pubmed
Tian,
MDA-7/IL-24 induces Bcl-2 denitrosylation and ubiquitin-degradation involved in cancer cell apoptosis.
2012,
Pubmed
Volinia,
A microRNA expression signature of human solid tumors defines cancer gene targets.
2006,
Pubmed
Wadhwa,
Achieving resistance specificity in prostate cancer.
2016,
Pubmed
Watahiki,
MicroRNAs associated with metastatic prostate cancer.
2011,
Pubmed
Wei,
Can urinary PCA3 supplement PSA in the early detection of prostate cancer?
2014,
Pubmed
Wiklund,
Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?
2010,
Pubmed
Yang,
Tumor-Penetrating Peptide Enhances Antitumor Effects of IL-24 Against Prostate Cancer.
2019,
Pubmed
Yu,
ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro.
2015,
Pubmed
